Professor Douglas Kell: New publications
Details of Professor Kell's new publications.
O’Hagan S, Swainston N, Handl J, Kell DB (2015) A ‘rule of 0.5′ for the metabolite-likeness of approved pharmaceutical drugs. Metabolomics, in the press; DOI 10.1007/s11306-11014-10733-z. Minor erratum.
Dunn WB, Lin W, Broadhurst D, Begley P, Brown M, Zelena E, Vaughan AA, Halsall A, Harding N, Knowles JD, Francis-McIntyre S, Tseng A, Ellis DI, O’Hagan S, Aarons G, Benjamin B, Chew-Graham S, Moseley C, Potter P, Winder CL, Potts C, Thornton P, McWhirter C, Zubair M, Burns A, Cruickshank JK, Jayson GC, Purandare N, Wu FW, Finn JD, Haselden JN, Nicholls AW, Wilson ID, Goodacre R, Kell DB (2015) Molecular phenotyping of a UK population: defining the human serum metabolome. Metabolomics, in the press. DOI: 10.1007/s11306-014-0707-1
Currin A, Swainston N, Day PJ, Kell DB: Synthetic biology for the directed evolution of protein biocatalysts: navigating sequence space intelligently. Chem Soc Rev 2015:online, DOI: 10.1039/c1034cs00351a.
Professor Douglas Kell has coauthored a very extensive review on the use of Synthetic Biology methods, both 'wet' (laboratory) and 'dry' (computational) in experimental directed evolution for biotransformations designed to perform chemical syntheses under mild, ambient conditions.
Kell, D. B. (2015) What would be the observable consequences if phospholipid bilayer diffusion of drugs into cells is negligible? Trends Pharmacol Sci 36, 15-21. DOI: 10.1016/j.tips.2014.10.005. Recommended by F1000Prime.
Kell, D. B. & Pretorius, E. (2015). The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen). Integr Biol. 7, 24-52. DOI: 10.1039/c4ib00173g.
This paper has been badged as a hot paper by the RSC. Professor Douglas Kell has continued a very effective BBSRC-funded collaboration with Prof Resia Pretorius (South Africa), developing novel and minimally invasive procedures for detecting inflammatory diseases, and showing the unity of the underlying processes.
Kell DB, Lurie-Luke E: The virtue of innovation: innovation through the lenses of biological evolution. J R Soc Interface 2015; 12:20141183. DOI: 10.1098/rsif.2014.1183.
Pretorius, E., Swanepoel, A. C., Buys, A. V., Vermeulen, N., Duim, W. & Kell, D. B. (2014). Eryptosis as a marker of Parkinson’s disease. Aging 6, 788-819.
Kell, D. B. & Oliver, S. G. (2014). How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Front Pharmacol, 5, 231.
Professor Douglas Kell has continued to develop the ostensibly heretical idea that small-molecule drugs do not normally enter cells by 'passive' diffusion through the lipid bilayers of cells, which were selected by evolution not to allow this. Instead, he has adduced evidence from the extensive literature, as well as in his own experiments, that they normally hitchhike on protein transporters that are naturally involved in intermediary metabolism. This has led to a novel 'rule of 0.5' for recognising the utility of the 'metabolite-likeness' of marketed pharmaceutical drugs.